Medtech fundings in March 2015

Fundings for medical technologies in March 2015 totaled $542 million, led by the $57 million funding of EndoChoice, Inc.

Below are the top fundings for the month.

Company, fundingProduct/technology
EndoChoice, Inc., has raised $57 million in a round of funding, according to the companyEndoscopes and other instrumentation in gastroenterology
Apollo Endosurgery, Inc., has closed a $50 million secured term loan according to the companyMinimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures
Semma Therapeutics has raised $44 million in a Series A round of funding according to the companyCell therapy for type I diabetes
Svelte Medical Systems, Inc., has raised $38.01 million of a planned $48.74 million round of funding according to a regulatory filingDrug eluting and other coronary stents
Auxogyn, Inc., has raised $34.32 million of a planned $40 million round of funding according to a regulatory filingDiagnostic and other technologies focused on women’s reproductive health
SteadyMed Therapeutics, Inc., has raised $39.95 million in its IPO according to press reportsPatch-pump drug delivery technology
Hansen Medical, Inc., has raised $35 million in a round of funding according to a regulatory filingIntravascular robotics

For the complete list of medtech fundings in March 2015, see link.

For a historical list of the individual fundings in medtech, by month, since 2009, see link.

Where to invest? How about in innovation?

The recent formation of an index focused on health product innovators illustrates both the upside and the stability of the medtech arena. 

The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding all new formulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies which receive original PMA approvals for new medical devices are included in the index, excluding the less rigorous and more numerous 510(k) applications.

The goal of the index is to track the performance of companies which are developing innovative new drugs and medical devices to see whether their investment in R&D pays off in the form of better stock price performance compared to benchmark ETFs for pharma, biotech, medical devices, and the overall healthcare sector.

ETF Innovators